Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.70 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.70 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.70 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.70 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.70 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.70 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642635 | 0.91 | L3MBTL1 (0.66) | L3MBTL1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL7943306 | 0.84 | L3MBTL1 (1.00) | L3MBTL1ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL20353604 | 0.82 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL519262 | 0.82 | PRKAA2 (1.00) | L3MBTL1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Piberaline SCHEMBL6018379 | 0.82 | PRKAB2 (0.50) | L3MBTL1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1461593 | 0.82 | L3MBTL1 (0.86) | L3MBTL1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL15853631 | 0.81 | RORC (0.64) | L3MBTL1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12120399 | 0.80 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL16797903 | 0.80 | EPHX2 (0.64) | L3MBTL1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL7955601 | 0.80 | L3MBTL1 (0.89) | L3MBTL1ALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1039 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2012116278-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101484152-A | Therapeutic combination for painful medical conditions | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-07-15 | — | — | CN | claimed |
| EP-2026788-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2009-02-25 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007141018-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2007-12-13 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | SRZ PROPERTIES, INC. (US) | 2007-02-22 | — | — | US | claimed |
| EP-1725222-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | Pharmacia Corporation (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2025129358-A1 | STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES | INTELGENX CORP. (CA) | 2025-06-26 | — | — | WO | disclosed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| US-4647599-A | Sustained release pharmaceutical tablets and process for the preparation thereof | EGYT GYOGYSZERVEGYESZETI CYAR (HU) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | GRIN2B, GRIN2A, GRIN3A | L3MBTL1 2787/4885PRKAB2 2398/4885PRKAG1 2754/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | L3MBTL1 2100/4885PRKAB2 3245/4885PRKAG1 3817/4885 |
| US-12109219-B2 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | L3MBTL1 4843/4885PRKAB2 1332/4885PRKAG1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.